ESTRO 2024 - Abstract Book

S2840

Interdisciplinary - Health economics & health services research

ESTRO 2024

Conclusion:

The implementation of ultra-hypofractionation in breast cancer RT in 2022 resulted in significant cost savings for both Spanish healthcare system and patients. In addition, empty RT slots were used by other patients, helping to reduce our waiting lists.

Keywords: Ultra-hypofractionation, economic impact, breast

References:

Murray Brunt A, Haviland JS, Wheatley DA, Sydenham MA, Alhasso A, Bloomfield DJ, Chan C, Churn M, Cleator S, Coles CE, Goodman A, Harnett A, Hopwood P, Kirby AM, Kirwan CC, Morris C, Nabi Z, Sawyer E, Somaiah N, Stones L, Syndikus I, Bliss JM, Yarnold JR; FAST-Forward Trial Management Group. Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non inferiority, randomised, phase 3 trial. Lancet. 2020 May 23;395(10237):1613-1626. doi: 10.1016/S0140 6736(20)30932-6. Epub 2020 Apr 28. PMID: 32580883; PMCID: PMC7262592. Brunt AM, Wheatley D, Yarnold J, Somaiah N, Kelly S, Harnett A, Coles C, Goodman A, Bahl A, Churn M, Zotova R, Sydenham M, Griffin CL, Morden JP, Bliss JM; FAST-Forward Trial Management Group. Acute skin toxicity associated with a 1-week schedule of whole breast radiotherapy compared with a standard 3-week regimen delivered in the UK FAST-Forward Trial. Radiother Oncol. 2016 Jul;120(1):114-8. doi: 10.1016/j.radonc.2016.02.027. Epub 2016 Apr 1. PMID: 27046390; PMCID: PMC4998960. Nugent K, Quinlan E, Cleary S, O'Driscoll H, Rohan C, Trousdell J, Williams J, Dunne M, McArdle O, Duane FK. Implementation of 26 Gy in five fractions over 1 week adjuvant radiotherapy for breast cancer: Prospective report of acute skin toxicity and consideration of resource implications. Breast. 2023 Feb;67:55-61. doi: 10.1016/j.breast.2022.12.008. Epub 2022 Dec 16. PMID: 36603414; PMCID: PMC9756602. Ward MC, Recht A, Vicini F, Al-Hilli Z, Asha W, Chadha M, Abraham A, Thaker N, Khan AJ, Keisch M, Shah C. Cost Effectiveness Analysis of Ultra-Hypofractionated Whole Breast Radiation Therapy Alone Versus Hormone Therapy Alone or Combined Treatment for Low-Risk ER-Positive Early Stage Breast Cancer in Women Aged 65 Years and